论文信息 - Response: Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting - 字舞流文

Response: Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting

J. Versmissen | T. van Gelder | J. Doorduijn | B. Koch | F. Atiq | A. E. Broers | L. Andrews

[1] J. Esteve,et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transpl , 2016, Cancer.

[2] J. Versmissen,et al. A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib , 2016, European Journal of Clinical Pharmacology.

[3] A. Salihoglu,et al. Relapse after allogeneic hematopoietic stem cell transplant in patients with chronic myeloid leukemia: tyrosine kinase inhibitors, donor lymphocyte infusions or both? , 2015, Leukemia & lymphoma.

[4] F. Şahin,et al. Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients , 2013, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[5] T. Buclin,et al. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. , 2011, Blood.